Skip to main content

Advertisement

SpringerLink
Log in

Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

CMC-544 (inotuzumab ozogamicin) is a CD22-specific immunoconjugate of calicheamicin currently being evaluated in patients with non-Hodgkin’s B-cell lymphoma (BCL). CHOP and CVP represent untargeted combination chemotherapy comprised of cyclophosphamide, vincristine and prednisone with or without doxorubicin, commonly used in the treatment of NHL. Here, we describe anti-tumor efficacy of CMC-544, CHOP or CVP against human BCL xenografts.

Methods

In vitro, human BCLs were cultured with CMC-544 or individual constituents of CHOP for inhibition of their growth. In vivo, immunocompromised mice with established BCL xenografts were administered CHOP, CVP or CMC-544 to monitor their survival and BCL growth.

Results

In vitro, CMC-544 was more potent in causing growth inhibition of various BCL than cyclophosphamide, doxorubicin, vincristine or dexamethasone. In vivo, treatment with CHOP or CVP inhibited growth of BCL xenografts for up to 40 days after which BCL relapsed. Tumor growth inhibition by CMC-544 (>100 days) lasted longer than that by CHOP or CVP. BCL xenografts that relapsed after the treatment with CHOP or CVP were far less responsive to CHOP or CVP re-treatment but regressed upon subsequent treatment with CMC-544. CVP could be co-administered with suboptimal doses of CMC-544, while CHOP could be administered on alternant days with CMC-544 to cause enhanced regression of established BCL xenografts.

Conclusion

Preclinically, CMC-544 provides greater therapeutic benefit than CVP or CHOP against BCL xenografts. CMC-544 may also be co-administered with standard chemotherapeutic regimens in the treatment of B-NHL for superior anti-tumor activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Abbreviations

BCL:

B-cell lymphoma

CalichDMH:

N-acetyl gamma calicheamicin dimethyl hydrazide

CHOP:

Cyclophosphamide doxorubicin vincristine prednisone

CVP:

Cyclophosphamide vincristine prednisone

B-NHL:

Non-Hodgkin’s B-cell lymphoma

References

  1. Damle NK (2004) Tumor-targeted chemotherapy with immunoconjugates of calicheamicin. Expert Opin Biol Ther 4:1445–1452

    Article  PubMed  CAS  Google Scholar 

  2. Bross PF, Beitz J, Chen G et al (2001) Gemtuzumab ozogamicin: approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7:1490–1496

    PubMed  CAS  Google Scholar 

  3. Ghobrial I, Witzig T (2004) Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin’s lymphoma. Oncology 18:623–630

    PubMed  Google Scholar 

  4. DiJoseph JF, Armellino DC, Boghaert E et al (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B lymphoid malignancies. Blood 103:1807–1814

    Article  PubMed  CAS  Google Scholar 

  5. Zein N, Sinha A, McGahren W, Ellestad G (1988) Calicheamicin γI: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 240:1198–1201

    Article  PubMed  CAS  Google Scholar 

  6. Hamann PR, Hinman LM, Beyer CF et al (2002) An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconj Chem 13:40–46

    Article  CAS  Google Scholar 

  7. DiJoseph JF, Goad ME, Dougher MM et al (2004) Potent and specific anti-tumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res 10:8620–8629

    Article  PubMed  CAS  Google Scholar 

  8. DiJoseph JF, Dougher MM, Kalyandrug LB et al (2006) Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin’s B-cell lymphoma. Clin Cancer Res 12:242–249

    Article  PubMed  CAS  Google Scholar 

  9. Advani A, Gisselbrecht EGC, Rohatiner A et al (2005) Preliminary report of a phase 1 study of CMC-544, an antibody-targeted chemotherapy agent, in patients with B-cell non Hodgkin’s lymphoma (NHL). Blood 106:230a

    Google Scholar 

  10. Fayad L, Patel H, Verhoef G et al (2006) Clinical activity of the immunoconjugate CMC-544 in B-cell malignancies: Preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase 1 study. Blood 108:766a

    Google Scholar 

  11. Tobinai K, Ogura M, Hatake K et al (2008) Phase I pharmacokinetic study of inotuzumab ozogamicin (CMC-544) as a single agent in Japanese patients with follicular lymphoma pretreated with rituximab. Blood 112:1565

    Google Scholar 

  12. Fayad L, Patel H, Verhoef G et al (2008) Safety, clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymphoma: preliminary report of a phase 1/2 study. Blood 112:266

    Google Scholar 

  13. Fisher RI, Gaynor ER, Dalhberg S et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328:1002–1006

    Article  PubMed  CAS  Google Scholar 

  14. McKelevet EM, Gottlieb JA, Wilson HE et al (1976) Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38:1484–1493

    Article  Google Scholar 

  15. Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242

    Article  PubMed  CAS  Google Scholar 

  16. DiJoseph JF, Popplewell A, Tickle S et al (2005) Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunol Immunother 54:11–24

    Article  PubMed  CAS  Google Scholar 

  17. Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM (2000) The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenografts model. Clin Cancer Res 6:4950–4956

    PubMed  CAS  Google Scholar 

  18. Jenkins JS, Sampson PA (1967) Conversion of cortisone to cortisol and prednisone to prednisolone. Br Med J 2:205–207

    Article  PubMed  CAS  Google Scholar 

  19. Flavell DJ, Boehm DA, Emery L, Noss A, Ramsey A, Flavell SU (1995) Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19-and anti-CD38-saporin immunotoxins used alone in combination than with either immunotoxin alone. Int J Cancer 62:337–344

    Article  PubMed  CAS  Google Scholar 

  20. Hamann P, Hinman L, Hollander I et al (2002) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconj Chem 13:47–58

    Article  CAS  Google Scholar 

  21. Clavio M, Albarello A, Vignolo L (2007) Adding low-dose gemtuzumab ozogamicin to fludarabine, Aca-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. Br J Haematol 138:186–195

    Article  PubMed  CAS  Google Scholar 

  22. Burnett AK, Kell WJ, Goldstone AH et al (2006) The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity. Preliminary analysis of 1115 patients in the MRC AML15 trial. Blood 13:8a

    Google Scholar 

Download references

Author information

Author notes

  1. Nitin K. Damle

    Present address: Endo Pharmaceuticals, 100 Endo Boulevard, Chadds Ford, PA, 19317, USA

Authors and Affiliations

  1. Oncology Discovery, Wyeth Research, 401 North Middletown Road, Pearl River, NY, 10965, USA

    John F. DiJoseph, Maureen M. Dougher, Deborah Y. Evans, Bin-Bing Zhou & Nitin K. Damle

Authors
  1. John F. DiJoseph
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maureen M. Dougher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Deborah Y. Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bin-Bing Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nitin K. Damle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John F. DiJoseph.

Additional information

All authors were employees of Wyeth Research during the conduct of this investigation. CMC-544 is a collaboration product being jointly developed by Wyeth Research and UCB Celltech, Slough, UK.

Rights and permissions

Reprints and permissions

About this article

Cite this article

DiJoseph, J.F., Dougher, M.M., Evans, D.Y. et al. Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP. Cancer Chemother Pharmacol 67, 741–749 (2011). https://doi.org/10.1007/s00280-010-1342-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-010-1342-9

Keywords

Search

Navigation